The BioHub - by Avetix

Today on The BioHub, I'm delighted to be joined by Dr. Aarash Bordbar, Co-Founder and Chief Executive Officer of Sinopia Biosciences.

Aarash has built his career at the intersection of computational biology, systems biology and drug discovery, with a particular focus on understanding complex biological systems and translating that knowledge into new therapeutic approaches.

He co-founded Sinopia Biosciences with a vision of harnessing computational modelling and data-driven approaches to transform drug discovery, bringing together biology, mathematics and technology to tackle some of the most challenging questions in medicine.

Today, we're going to explore Aarash's journey through the field, the founding and evolution of Sinopia, how computational biology is changing the drug discovery landscape, and what the future might look like as AI and advanced modelling become increasingly integrated into biotechnology.

In this episode of The BioHub, Amber is joined by Dr. Sean Ekins, Founder and CEO of Collaborations Pharmaceuticals.

Sean shares his perspective on the evolving role of machine learning in drug discovery, how computational approaches can support rare and neglected disease research, and what it really takes to move from prediction to meaningful therapeutic development.

They also discuss the opportunities and limitations of AI in chemistry, the importance of scientific collaboration, and some of the wider questions around responsible innovation and dual-use risk as generative drug discovery continues to develop.

n this episode of The BioHub, we welcome Jason Goodson, Chief Operating Officer at PleoPharma, a clinical-stage biotechnology company developing innovative treatments for cannabis use disorder and cannabis withdrawal syndrome.

With millions of Americans affected by cannabis use disorder and no FDA-approved medications specifically targeting cannabis withdrawal, PleoPharma is working to address a significant unmet need through its lead candidate, PP-01, now in pivotal Phase 3 development.

Jason shares insights into the growing market for addiction therapeutics, the clinical and commercial potential of PP-01, and the challenges of bringing a first-in-class treatment to market.

We also explore the strategic decisions behind scaling a clinical-stage biotech, from financing and partnerships to commercial readiness, leadership, and building the right team for future growth.

Today, we’re joined by Erick Lucera, Chief Financial Officer, and Vikram Ranade, Chief Business Officer at Dyne Therapeutics. We’ll be discussing their individual journeys through biotech, what attracted them to Dyne, and the company’s mission to develop transformative treatments for people living with genetically driven neuromuscular diseases. We’ll also explore the strategy behind building a biotech towards commercialisation, the financial and business development challenges involved, and their perspectives on the wider biotech landscape.

In this episode of The BioHub Podcast, Ben is joined by Dr. John Yu, CEO and Chairman of Kairos Pharma, a clinical-stage biotechnology company developing innovative therapies to overcome drug resistance and immune suppression in cancer.

Dr. Yu brings a unique perspective from his extensive career in neurosurgery, oncology, immunology, and biotechnology entrepreneurship. Together, they explore his journey from academic medicine into biotech leadership, the science behind Kairos Pharma's approach to tackling cancer drug resistance, and the development of its lead candidate, ENV105, which targets CD105 to potentially restore sensitivity to existing cancer treatments.

The conversation also examines the challenges of translating academic discoveries into clinical therapies, building and financing an emerging biotechnology company, and the opportunities ahead for improving cancer treatment outcomes.

An insightful discussion on scientific innovation, entrepreneurship, and the journey from breakthrough research to meaningful patient impact.

In this episode of The BioHub by Avetix, I’m joined by Sam Reich, CEO of SAB BIO.

Sam shares his unconventional journey from leaving his PhD to build his first biotech, through founding and selling companies, working with influential industry figures like Phil Frost, and eventually leading Big Cypress Acquisition Corp.

We discuss how that journey brought him to SAB BIO, why the company became the right opportunity, the challenges behind its strategic pivot towards type 1 diabetes, and what it takes to keep adapting when the path of a biotech changes.

We also explore the lessons Sam has learned from building, financing and leading companies across multiple stages, and what comes next for SAB as it works to develop a disease-modifying treatment for type 1 diabetes.

In this episode of The BioHub, Amber is joined by Dr. Garry Pairaudeau, Co-Founder and CEO, and Dr. Anthony Bradley, Co-Founder and CSO of Dalton Tx.

Having previously worked together at Exscientia, Garry and Anthony went on to co-found Dalton Tx. bringing together AI, scientific expertise and software engineering to help accelerate drug discovery.

We explore their journey the challenges of translating advances in AI into meaningful scientific impact, and the importance of separating genuine innovation from industry hype.

We also discuss the evolving role of AI in drug discovery, building a science-driven company, and what the future could hold for AI-enabled therapeutics.

Why spend months recreating research tools that another lab has already built?

In this episode of The BioHub, we’re joined by Greg Crescenzi from Addgene to discuss how sharing scientific materials can reduce duplicated work, save researchers time and help biotech discoveries move faster.

From plasmids and CRISPR tools to viral vectors and antibodies, Greg explains how Addgene helps scientists build on existing research—and why improving access between academia and industry is the next challenge.

We cover:

• The frustration that sparked Addgene’s founding
• How sharing research tools helped CRISPR reach thousands of organisations
• The barriers between academic research and commercial biotech
• Partnerships supporting better sequencing and new research tools
• Why unsuccessful experiments contain information worth sharing
• Where AI and Addgene’s research data could create new opportunities

Subscribe to The BioHub for more conversations with the people advancing biotech.

#Biotech #Addgene #CRISPR #BioHub

In this episode of The BioHub by Avetix, I’m joined by Marshall Fordyce, Founder and CEO of Vera Therapeutics.

Marshall shares his journey from medicine and HIV drug development at Gilead to founding Vera, and how that experience shaped his belief in the power of building medicines that can genuinely change the course of disease.

We discuss what patient-centricity looks like in practice, the thinking behind Vera’s Phase III strategy, and the company’s transition from development-stage biotech into commercial launch. Marshall also shares his framework for building biotech companies, why people and capital discipline matter just as much as the science, and what comes next for Vera as it continues the US launch of Trutacna.

In this episode of The BioHub, Amber is joined by Dr. Chris Moxham, Co-founder and CEO of Transcripta Bio, and Clayton Mellina, CTO, to explore how transcriptomics and AI are opening up new possibilities in drug discovery.

Chris and Clayton explain how Transcripta connects the changes disease causes in cells with the effects of potential treatments. They discuss combining phenotypic screening with target-based discovery, finding new uses for existing medicines, and reducing risk earlier in development.

The conversation covers their work in genetically defined autism spectrum disorders and Huntington’s disease, their collaboration with Mayo Clinic, and how AI agents could help small scientific teams explore thousands of hypotheses.